Completed Enrollment

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)

I8H-MC-BDCX -

The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. Additional participants will continue to be enrolled in a maximum extended enrollment cohort.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
LY3209590, Insulin Degludec, Insulin Efsitora Alfa
Could I receive a Placebo?
No
Enrollment Goal
928
Trial Dates
Jun 3, 2022 - Apr 15, 2024
How long will I be in the trial?
Your participation could last about 57 weeks and may include up to 33 visits to the study center.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have type 2 diabetes mellitus (T2DM)
  • Participants must be taking diabetes medication 3 months before entering the study

Participants Must Not:

  • Participants must not have type 1 diabetes mellitus (T1DM)
  • Participants must not have had an episode of very low blood glucose level within the last 6 months of starting the study
  • Participants must not have had heart failure or other heart conditions

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources